Innovative Bispecific Nanobody Targeting ADGRA2 and LRP6 for Transformative Ocular Genetic Disorder Therapy

VHH-P247 is a novel, fully human nanobody-based bispecific antibody designed to target adhesion G protein-coupled receptor A2 (ADGRA2) and low-density lipoprotein receptor-related protein 6 (LRP6). Currently undergoing biological testing, VHH-P247 holds significant promise for the treatment of ocular genetic disorders. By engaging both ADGRA2 and LRP6, VHH-P247 aims to modulate key signaling pathways implicated in ocular pathology, potentially offering a new therapeutic avenue for patients with inherited retinal and ocular diseases. This innovative approach leverages advanced antibody engineering to achieve high specificity, stability, and favorable pharmacologic attributes.

Licensing Opportunity

VHH-P247 is available for out-licensing and collaborative development. We welcome inquiries from potential partners seeking innovative assets in the field of ocular genetic disorder therapeutics.

Development Phase

Modality

VHH-P247 is an agonistic, tetravalent, bispecific antibody that integrates a human monoclonal IgG1 targeting a G-protein coupled receptor, with each variable light chain fused at the N-terminus to a nanobody specific for LRP6, utilizing a short GSGGS linker. This modular design combines the structural advantages of nanobodies—such as small molecular weight, enhanced tissue penetration, and remarkable stability—with the effector functions of a classical IgG1 scaffold. The bispecific and multivalent architecture enables simultaneous or sequential engagement of two distinct yet complementary targets in ocular tissues, potentially optimizing downstream signaling and therapeutic efficacy in disorders with complex pathogenesis.

Target

ADGRA2 and LRP6 are critical molecular targets implicated in ocular homeostasis and disease. ADGRA2 is a G protein-coupled receptor involved in cell adhesion, migration, and signal transduction. LRP6 is a co-receptor essential for Wnt/β-catenin pathway signaling, pivotal in tissue development and regeneration. Both ADGRA2 and LRP6 are expressed in ocular tissues, including retinal cells, where they regulate developmental and repair processes. Genetic abnormalities affecting either ADGRA2 or LRP6 have been linked to vision impairment and degenerative eye diseases. Therapeutically targeting both ADGRA2 and LRP6 offers a compelling strategy for modulating multiple disease pathways simultaneously, positioning VHH-P247 as a strategically differentiated asset in the ocular genetic disorder treatment landscape.

Mechanism of Action

VHH-P247 acts as a dual agonist by engaging ADGRA2 and LRP6, thereby modulating their respective signaling cascades. By binding to and activating ADGRA2, VHH-P247 facilitates cellular adhesion and signaling processes that promote tissue integrity and repair in ocular environments. Concurrent activation and modulation of LRP6 enhance Wnt/β-catenin signaling, critically supporting cell survival and regeneration. The bispecific nanobody structure allows for coordinated signal modulation, potentially resulting in synergistic therapeutic benefits. Furthermore, the nanobody platform underlying VHH-P247 offers opportunities for further engineering, including the development of antibody–drug conjugates or multispecific formats to tailor future applications in ocular disease and beyond.

Ocular Genetic Disorders

Ocular genetic disorders encompass a broad spectrum of inherited diseases affecting the structure and function of the eye, such as retinitis pigmentosa, Leber congenital amaurosis, and various forms of retinal dystrophy. These conditions can lead to progressive vision loss or blindness, with a significant impact on quality of life. Globally, millions are affected by ocular genetic disorders, with prevalence varying according to genetic background and geographic region. Current therapies primarily include supportive care, gene therapy, and emerging molecular interventions. However, existing treatment options often face limitations such as restricted target populations, variable efficacy, and challenges in long-term disease modification. There remains a substantial unmet need for safe, effective, and broadly applicable therapies capable of addressing the underlying pathophysiology of these disorders. By directly targeting and activating pathways mediated by ADGRA2 and LRP6, VHH-P247 represents a promising next-generation approach to address critical gaps in the management of ocular genetic disorders, with the potential to improve visual outcomes and halt disease progression.